Preferred Label : MK-0524;
MeSH note : a potent orally active human prostaglandin D(2) receptor 1 antagonist; structure in
first source;
CISMeF synonym : laropiprant; (3R)-4-(4-chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta(b)indol-3-yl
acetic acid;
Is substance : O;
Origin ID : C518174;
UMLS CUI : C1871001;
MeSH term(s) associated for indexing
- Record concept(s)
- Semantic type(s)
- Validated automatic mappings to BTNT
Pelzont - nicotinic acid / laropiprant
https://www.ema.europa.eu/medicines/human/EPAR/Pelzont
2012
false
United Kingdom
English
French
syndication feed
Primary hypercholesterolemia (disorder)
mixed dyslipidemia
pregnancy
breast feeding
treatment outcome
adult
aged
drug interactions
drug evaluation, preclinical
drug therapy, combination
hypercholesterolemia
niacin
indoles
dyslipidemias
hypolipidemic agents
drug combinations
niacin
indoles
hypolipidemic agents
administration, oral
tablets
drug approval
drug labeling
MK-0524
MK-0524
nicotinic acid, combinations
laropiprant
laropiprant
drug evaluation
summary of product characteristics
package leaflet
---
Trevaclyn - nicotinic acid / laropiprant
https://www.ema.europa.eu/medicines/human/EPAR/Trevaclyn
2012
false
United Kingdom
French
English
syndication feed
Primary hypercholesterolemia (disorder)
mixed dyslipidemia
niacin
dyslipidemias
indoles
hypolipidemic agents
hypolipidemic agents
niacin
indoles
adult
aged
tablets
administration, oral
drug combinations
drug therapy, combination
drug interactions
drug approval
drug labeling
pregnancy
breast feeding
treatment outcome
hypercholesterolemia
MK-0524
MK-0524
nicotinic acid, combinations
laropiprant
laropiprant
drug evaluation
summary of product characteristics
package leaflet
---
Tredaptive - nicotinic acid / laropiprant
This medicine is now withdrawn from use in the European Union
https://www.ema.europa.eu/medicines/human/EPAR/Tredaptive
2012
false
United Kingdom
English
French
syndication feed
Primary hypercholesterolemia (disorder)
mixed dyslipidemia
niacin
hypolipidemic agents
indoles
dyslipidemias
drug approval
drug labeling
treatment outcome
drug combinations
drug therapy, combination
indoles
hypolipidemic agents
niacin
tablets
administration, oral
hypercholesterolemia
adult
aged
drug interactions
breast feeding
drug evaluation, preclinical
MK-0524
MK-0524
nicotinic acid, combinations
laropiprant
laropiprant
drug evaluation
summary of product characteristics
package leaflet
---
http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-11/tredaptive_-_ct-_8054.pdf
http://www.has-sante.fr/portail/jcms/c_1002687/tredaptive
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-06/tredaptive_ct_8054.pdf
2010
false
France
English
French
Primary hypercholesterolemia (disorder)
drug combinations
MK-0524
indoles
Delayed-Action preparations
administration, oral
niacin
hypolipidemic agents
insurance, health, reimbursement
dyslipidemias
receptors, prostaglandin
prostaglandin D2 receptor
receptors, immunologic
drug therapy, combination
adult
aged
treatment outcome
nicotinic acid, combinations
mixed dyslipidemia
evaluation of the transparency committee
receptors, immunologic
receptors, prostaglandin
laropiprant
---
http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-11/tredaptive_-_ct-_8054.pdf
http://www.has-sante.fr/portail/jcms/c_1020473/tredaptive-acide-nicotinique-/-laropiprant-hypolipemiant
2010
France
French
Primary hypercholesterolemia (disorder)
drug combinations
niacin
administration, oral
MK-0524
indoles
nicotinic acid, combinations
insurance, health, reimbursement
hypolipidemic agents
Delayed-Action preparations
prostaglandin D2 receptor
receptors, immunologic
receptors, prostaglandin
dyslipidemias
treatment outcome
receptors, immunologic
receptors, prostaglandin
laropiprant
guidelines for drug use
evaluation of the transparency committee
---
